A vapourized δ9-tetrahydrocannabinol (δ9-THC) delivery system part II: Comparison of behavioural effects of pulmonary versus parenteral cannabinoid exposure in rodents

Journal of Pharmacological and Toxicological Methods

Volumn 70, Issue 1, 2014, Pages 112-119

  Manwell, Laurie A ^a,b,c   Ford, Brittany ^a   Matthews, Brittany A ^a   Heipel, Heather ^a   Mallet, Paul E ^a  

^a WILFRID LAURIER UNIVERSITY   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cross sensitization; Food consumption; Locomotion; Pulmonary administration; Rat

Indexed keywords

MORPHINE; TETRAHYDROCANNABINOLIC ACID; CANNABINOID; DRONABINOL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; CROSS ALLERGY; FLUID INTAKE; FOOD INTAKE; LOCOMOTION; MALE; NONHUMAN; RAT; RELIABILITY; TASK PERFORMANCE; TOXICITY TESTING; VAPORIZATION; ANIMAL; ANIMAL MODEL; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG; MOTOR ACTIVITY; PROCEDURES; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INHALATION; ANIMALS; CANNABINOIDS; DRONABINOL; DRUG DELIVERY SYSTEMS; INJECTIONS, INTRAPERITONEAL; LUNG; MALE; MODELS, ANIMAL; MORPHINE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84904277084     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2014.06.004     Document Type: Article

References (37)

1. Abel E.L. Effects of marihuana on the solution of anagrams, memory and appetite. Nature 1971, 231:260-261.
2. Abel E.L. Cannabis: Effects on hunger and thirst. Behavioral Biology 1975, 15:255-281.
3. Aldington S., Harwood M., Cox B., Weatherall M., Beckert L., Hansell A., et al. Cannabis and respiratory disease risk group. Cannabis use and risk of lung cancer: A case-control study. European Respiratory Journal 2008, 31:280-286.
4. Berthiller J., Straif K., Boniol M., Voirin N., Benhaim-Luzon V., Ayoub W.B., et al. Cannabis smoking and risk of lung cancer in men: A pooled analysis of three studies in Maghreb. Journal of Thoracic Oncology 2008, 3:1398-1403.
5. 9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology 2001, 158:259-266.
6. 9-THC. Pharmacology, Biochemistry and Behavior 1976, 4:635-638.
7. Fried P.A., Neiman G.W. Inhalation of cannabis smoke in rats. Pharmacology, Biochemistry, and Behavior 1973, 1:371-378.
8. Glick S.D., Milloy S. Increased and decreased eating following THC administration. Psychonomic Science 1972, 29:6.
9. Graceffo T.J., Robinson J.K. Delta-9-tetrahydrocannabinol (THC) fails to stimulate consumption of a highly palatable food in the rat. Life Sciences 1998, 62:85-88.
10. Greenberg I., Kuehnle J., Mendelson J.H., Bernstein J.G. Effects of marijuana use on body weight and energy intake in humans. Psychopharmacology 1976, 49:79-84.
11. Hashibe M., Straif K., Tashkin D.P., Morgenstern H., Greenland S., Zhang Z.F. Epidemiological review of marijuana use and cancer risk. Alcohol 2005, 35:265-275.
12. Hazekamp A., Ruhaak R., Zuurman L., van Gerven J., Verpoorte R. Evaluation of vaporizing device (Volcano ®) for the pulmonary administration of tetrahydrocannabinol. Journal of Pharmaceutical Sciences 2006, 95:1308-1317.
13. Järbe T.U., DiPatrizio N.V. Delta-9-THC induced hyperphagia and tolerance assessment: Interactions between the CB1 receptor agonist delta-9-THC and the CB1 receptor antagonist SR141716 (rimonabant) in rats. Behavioural Pharmacology 2005, 16:373-380.
14. Kirkham T.C., Williams C.M. Endogenous cannabinoids and appetite. Nutrition Research Reviews 2001, 14:65-86.
15. 9-THC stimulates food intake in Lewis rats: Effects on chow, high-fat and sweet high-fat diets. Pharmacology, Biochemistry and Behavior 2001, 68:539-543.
16. 9-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 2001, 41:118-129.
17. Lichtman A.H., Sheikh S.M., Loh H.H., Martin B.R. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. Journal of Pharmacology and Experimental Therapeutics 2001, 298:1007-1014.
18. Manwell L.A., Charchoglyan A., Brewer D., Matthews B., Heipel H., Mallet P.E. A vapourized δ9-tetrahydrocannabinol (δ9-THC) delivery system. Part I: Development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents. Journal of Pharmacological and Toxicological Methods 2014, (in this issue, Accepted June 5).
19. Naef M., Russman S., Petersen-Felix S., Brenneisen R. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. Journal of Pharmaceutical Sciences 2004, 1176-1184.
20. Niyuhire F., Varvel S.A., Martin B.R., Lichtman A.H. Exposure to marijuana smoke impairs memory retrieval in mice. Journal of Pharmacology and Experimental Therapeutics 2007, 322:1067-1075.
21. Norwood C.S., Cornish J.L., Mallet P.E., McGregor I.S. Pre-exposure to the cannabinoid receptor agonist CP 55,940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. European Journal of Pharmacology 2003, 465:105-114.
22. Reece A.S. Review: Chronic toxicology of cannabis. Clinical Toxicology 2009, 47:517-524.
23. Roth M.D., Marques-Magallanes J.A., Yuan M., Sun W., Tashkin D.P., Hankinson O. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta(9)-tetrahydrocannabinol. American Journal of Respiratory Cell and Molecular Biology 2001, 24:339-344.
24. Sañudo-Peña M.C., Romero J., Seale G.E., Fernandez-Ruiz J.J., Walker J.M. Activational role of cannabinoids on movement. European Journal of Pharmacology 2000, 391:269-274.
25. Sarafian T.A., Magallanes J.A., Yuan M., Sun W., Tashkin D.P., Roth M.D. Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. American Journal of Respiratory Cell and Molecular Biology 1999, 20:1286-1293.
26. 9-tetrahydrocannabinol alters heroin-induced locomotor sensitization and fos-immunoreactivity. Neuropsychopharmacology 2005, 49:1189-1200.
27. Singh M.E., Verty A.N.A., Prince I., McGregor I.S., Mallet P.E. Modulation of morphine-induced For-immunoreactivity by the cannabinoid receptor antagonist SR141716. Neuropharmacology 2004, 47:1157-1169.
28. 9-tetrahydrocannabinol on food intake by rats. Psychopharmacologia 1974, 39:213-222.
29. Truitt E.B., Kinzer G.W., Berlo J.M. Behavioral activity in various fractions of marijuana smoke condensate in the rat. The Pharmacology of Marijuana 1976, 463-474. Raven, New York. M.C. Braude, S. Szara (Eds.).
30. Turner C.E., Bouwsma O.J., Billets S., Elsohly M.A. Constituents of Cannabis sativa L. XVIII: Electron voltage selected ion monitoring study of cannabinoids. Biomedical Mass Spectrometry 1980, 7:247-256.
31. Turner C.E., Elsohly M.A., Boeren E.G. Constituents of Cannabis sativa L. XVII: A review of the natural constituents. Journal of Natural Products 1980, 43:169-234.
32. Voirin N., Berthiller J., Benhaim-Luzon V., Boniol M., Straif K., Ayoub W.B., et al. Risk of lung cancer and past use of cannabis in Tunisia. Journal of Thoracic Oncology 2006, 1:577-579.
33. 9-tetrahydrocannabinol in the rat. Drug and Alcohol Dependence 2003, 71:169-177.
34. 9-THC. Physiology and Behavior 1998, 65:343-346.
35. 9-THC aerosol generated by a metered dose inhaler. Drug and Alcohol Dependence 2002, 67:259-267.
36. Wilson D.M., Varvel S.A., Harloe J.P., Martin B.R., Lichtman A.H. SR141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice. Pharmacology, Biochemistry and Behavior 2006, 85:105-113.
37. Zhang Z.F., Morgenstern H., Spitz M.R., Tashkin D.P., Yu G.P., Marshall J.R., et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiology, Biomarkers and Prevention 1999, 9:1071-1078.